Alto Neuroscience Files Q1 2025 10-Q
Ticker: ANRO · Form: 10-Q · Filed: 2025-05-14T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Alto Neuroscience Q1 2025 10-Q filed. Financials updated.
AI Summary
Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its financial status as of this date. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors with an update on Alto Neuroscience's financial health and operational progress during the first quarter of 2025, crucial for assessing the company's trajectory.
Risk Assessment
Risk Level: medium — As a clinical-stage pharmaceutical company, Alto Neuroscience faces inherent risks related to drug development and regulatory approvals.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-14 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
- 2024-03-31 — Prior Year Quarter End Date (Provides a comparative point for financial performance analysis.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 650 CASTRO STREET, SUITE 450 (address) — Company's business and mailing address
- MOUNTAIN VIEW, CA (location) — City and State of the company's address
FAQ
What is the primary business of Alto Neuroscience, Inc.?
Alto Neuroscience, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on May 14, 2025.
What is the company's principal business address?
The company's principal business address is 650 Castro Street, Suite 450, Mountain View, CA 94041.
What is the fiscal year end for Alto Neuroscience?
Alto Neuroscience's fiscal year ends on December 31.
From the Filing
0001999480-25-000037.txt : 20250514 0001999480-25-000037.hdr.sgml : 20250514 20250514163242 ACCESSION NUMBER: 0001999480-25-000037 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250514 DATE AS OF CHANGE: 20250514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 25946343 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 10-Q 1 alto-20250331.htm 10-Q alto-20250331 12-31 0001999480 2025 Q1 False xbrli:shares iso4217:USD iso4217:USD xbrli:shares alto:subsidiary alto:clinical-stageAsset xbrli:pure alto:tranche alto:invention alto:patentFamily 0001999480 2025-01-01 2025-03-31 0001999480 2025-05-09 0001999480 2025-03-31 0001999480 2024-12-31 0001999480 2024-01-01 2024-03-31 0001999480 2024-03-31 0001999480 2023-12-31 0001999480 us-gaap:CommonStockMember 2023-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001999480 us-gaap:RetainedEarningsMember 2023-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001999480 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001999480 us-gaap:RetainedEarningsMember 2024-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001999480 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001999480 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001999480 us-gaap:CommonStockMember 2025-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001999480 us-gaap:RetainedEarningsMember 2025-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001999480 us-gaap:IPOMember 2025-01-01 2025-03-31 0001999480 us-gaap:IPOMember 2024-01-01 2024-03-31 0001999480 alto:SeriesCPreferredStockFinancingMember 2025-01-01 2025-03-31 0001999480 alto:SeriesCPreferredStockFinancingMember 2024-01-01 2024-03-31 0001999480 us-gaap:IPOMember 2024-02-06 2024-02-06 0001999480 us-gaap:IPOMember 2024-02-06 0001999480 us-gaap:OverAllotmentOptionMember 2024-02-06 2024-02-06 0001999480 2024-02-01 2024-02-29 0001999480 alto:LaboratoryEquipmentMember 2025-03-31 0001999480 alto:LaboratoryEquipmentMember 2024-12-31 0001999480 us-gaap:FurnitureAndFixturesMember 2025-03-31 0001999480 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001999480 alto:ComputerSoftwareAndEquipmentMember 2025-03-31 0001999480 alto:ComputerSoftwareAndEquipmentMember 2024-12-31 0001999480 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001999480 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001999480 alto:LoanAndSecurityAgreementMember us-gaap:SecuredDebtMember 2022-12-16 0001999480 alto:DebtInstrumentTrancheFourMember alto:LoanAndSecurityAgreementMember us-gaap:SecuredDebtMember 2022-12-16 0001999480 alto:AmendedLoanAgreementMember us-gaap:SecuredDebtMember 2025-01-1